α7 nicotinic acetylcholine receptor agonist attenuates allergen-induced immediate nasal response in murine model of allergic rhinitis.

IF 1.1 4区农林科学 Q3 VETERINARY SCIENCES Journal of Veterinary Medical Science Pub Date : 2024-07-02 Epub Date: 2024-06-04 DOI:10.1292/jvms.24-0033

Shuhei Yamashita, Kento Miura, Anna Matsuura, Norimasa Yamasaki, Naoto Uda, Sawako Ogata, Naohisa Hosomi, Shotaro Nakajima, Noriko Kitamura, Minoru Gotoh, Akio Mori, Osamu Kaminuma

{"title":"α7 nicotinic acetylcholine receptor agonist attenuates allergen-induced immediate nasal response in murine model of allergic rhinitis.","authors":"Shuhei Yamashita, Kento Miura, Anna Matsuura, Norimasa Yamasaki, Naoto Uda, Sawako Ogata, Naohisa Hosomi, Shotaro Nakajima, Noriko Kitamura, Minoru Gotoh, Akio Mori, Osamu Kaminuma","doi":"10.1292/jvms.24-0033","DOIUrl":null,"url":null,"abstract":"<p><p>The expression of nicotinic acetylcholine receptor (nAChR) subunits on various immune cells suggests their involvement in allergic rhinitis. However, how exactly they contribute to this pathogenesis is not yet confirmed. Our present study examined the therapeutic potential of GTS-21, an α7 nAChR agonist, for treating allergic rhinitis by employing its mouse models. GTS-21 treatment reduced allergen-induced immediate nasal response in ovalbumin (OVA)-sensitized model. However, nasal hyperresponsiveness or eosinophil infiltration elicited in either the OVA-sensitized or T helper 2 cell-transplanted model was not affected by GTS-21. GTS-21 did not alter allergen-induced passive cutaneous anaphylaxis response in anti-dinitrophenyl IgE-sensitized mice. This evidence implies GTS-21's potential to alleviate allergic rhinitis without perturbing T cells or mast cells.</p>","PeriodicalId":49959,"journal":{"name":"Journal of Veterinary Medical Science","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251814/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Veterinary Medical Science","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1292/jvms.24-0033","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

The expression of nicotinic acetylcholine receptor (nAChR) subunits on various immune cells suggests their involvement in allergic rhinitis. However, how exactly they contribute to this pathogenesis is not yet confirmed. Our present study examined the therapeutic potential of GTS-21, an α7 nAChR agonist, for treating allergic rhinitis by employing its mouse models. GTS-21 treatment reduced allergen-induced immediate nasal response in ovalbumin (OVA)-sensitized model. However, nasal hyperresponsiveness or eosinophil infiltration elicited in either the OVA-sensitized or T helper 2 cell-transplanted model was not affected by GTS-21. GTS-21 did not alter allergen-induced passive cutaneous anaphylaxis response in anti-dinitrophenyl IgE-sensitized mice. This evidence implies GTS-21's potential to alleviate allergic rhinitis without perturbing T cells or mast cells.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

α7烟碱乙酰胆碱受体激动剂可减轻过敏原诱导的小鼠过敏性鼻炎模型的即时鼻腔反应。

烟碱乙酰胆碱受体（nAChR）亚基在各种免疫细胞上的表达表明，它们与过敏性鼻炎有关。然而，它们究竟是如何参与这一发病机制的尚未得到证实。本研究利用小鼠模型研究了α7 nAChR 激动剂 GTS-21 治疗过敏性鼻炎的潜力。在卵清蛋白（OVA）致敏模型中，GTS-21 可降低过敏原诱导的即刻鼻反应。然而，GTS-21 并不影响 OVA 致敏模型或 T 辅助细胞 2 移植模型引起的鼻腔高反应性或嗜酸性粒细胞浸润。GTS-21 不会改变抗二硝基苯基 IgE 致敏小鼠的过敏原诱导的被动皮肤过敏性休克反应。这些证据表明，GTS-21 有可能在不干扰 T 细胞或肥大细胞的情况下缓解过敏性鼻炎。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Veterinary Medical Science 农林科学-兽医学

CiteScore

2.30

自引率

8.30%

发文量

230

审稿时长

9-18 weeks

期刊介绍： JVMS is a peer-reviewed journal and publishes a variety of papers on veterinary science from basic research to applied science and clinical research. JVMS is published monthly and consists of twelve issues per year. Papers are from the areas of anatomy, physiology, pharmacology, toxicology, pathology, immunology, microbiology, virology, parasitology, internal medicine, surgery, clinical pathology, theriogenology, avian disease, public health, ethology, and laboratory animal science. Although JVMS has played a role in publishing the scientific achievements of Japanese researchers and clinicians for many years, it now also accepts papers submitted from all over the world.